<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Poorly differentiated cancer from an unknown primary site</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Poorly differentiated cancer from an unknown primary site</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Poorly differentiated cancer from an unknown primary site</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John D Hainsworth, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Anthony Greco, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">George P Canellos, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cancer of unknown primary site (CUP) is a relatively common clinical entity, accounting for approximately 2 percent of all invasive cancer diagnoses [<a href="#rid1">1</a>]. Within this category, tumors from many primary sites with varying biology are represented. Most CUP are adenocarcinomas and can be recognized by routine histologic examination. However, 20 to 25 percent of CUPs are poorly differentiated and cannot be precisely characterized by histologic examination. Approximately 80 percent of these poorly differentiated tumors have features of carcinoma and are termed "poorly differentiated carcinoma" after initial pathologic examination. In the remainder, histologic examination results in the diagnosis of "poorly differentiated neoplasm," signifying the inability to distinguish between carcinoma, melanoma, lymphoma, or sarcoma.</p><p>Every attempt should be made to arrive at the most specific diagnosis possible, since the treatments for various cancers in this group can be quite different and may be curative in some patients. The diagnostic approach to poorly differentiated cancers of unknown primary site will be reviewed here, along with the prognostic and therapeutic implications.</p><p>Other relevant topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4878.html" rel="external">"Overview of the classification and management of cancers of unknown primary site"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4880.html" rel="external">"Squamous cell carcinoma of unknown primary site"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/14251.html" rel="external">"Head and neck squamous cell carcinoma of unknown primary"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4876.html" rel="external">"Neuroendocrine neoplasms of unknown primary site"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/766.html" rel="external">"Axillary node metastases with occult primary breast cancer"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL EVALUATION</span></p><p>The evaluation of the patient with a cancer of unknown origin usually begins with a biopsy that documents metastatic cancer. Optimum evaluation requires a number of clinical and pathologic studies. (See <a class="local">'Pathologic evaluation'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>Once a diagnosis of malignancy has been established, the following procedures must fail to identify an anatomic primary site before the diagnosis of CUP can be made: history, physical examination, urinalysis, serum chemistries, complete blood counts, serum PSA (males), mammography (females), and computerized tomography (CT) or magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis. In addition, focused clinical evaluation of signs and symptoms suggestive of metastatic cancer should be performed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum levels of human chorionic gonadotropin (hCG) and alpha-fetoprotein (AFP) should be obtained in all patients with the initial diagnosis of "poorly differentiated neoplasm" or "poorly differentiated carcinoma," since significant elevations of these tumor markers suggest the diagnosis of extragonadal germ cell tumor. (See  <a class="medical medical_review" href="/z/d/html/2998.html" rel="external">"Extragonadal germ cell tumors involving the mediastinum and retroperitoneum"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positron emission tomography (PET) and PET/CT scans can identify a primary site in a minority of patients. However, one prospective study did not show superiority of PET/CT when compared with CT alone [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other traditional serum tumor markers, such as carcinoembryonic antigen (CEA), CA-125, CA19-9, and CA15-3, are not useful in identifying the primary site or tissue of origin. However, these markers are often elevated, and serial measurement may be useful in subsequently following the response to therapy in an individual patient.</p><p></p><p class="headingAnchor" id="H2285843331"><span class="h1">PATHOLOGIC EVALUATION</span></p><p class="headingAnchor" id="H525608402"><span class="h2">Initial biopsy review</span><span class="headingEndMark"> — </span>The first step in the pathologic evaluation of a patient with poorly differentiated CUP is review of the biopsy material.</p><p>A nonspecific light microscopic diagnosis can be due to a biopsy specimen that is very small or poorly preserved. In particular, tissue obtained by fine needle aspiration (FNA) provides inadequate diagnostic material in patients with poorly differentiated tumors, because histologic detail is poorly preserved and the ability to perform special studies is limited by the small amount of tissue available.</p><p>Examination of poorly differentiated malignancies using routine light microscopy/histology alone is inadequate. There are no light microscopic features that can reliably distinguish between these different tumor groups or between treatment-sensitive and treatment-resistant cancers. Even with careful retrospective review of these cases, some tumors that are highly responsive to specific treatment regimens (germ cell tumor, lymphoma) were not readily distinguished morphologically [<a href="#rid3">3</a>].</p><p>Thus, tumor biopsies from these patients should undergo additional pathologic evaluation using immunohistochemistry (IHC). If the IHC results are inconclusive, a molecular cancer classifier assay (MCCA) should be performed to better characterize the cancer and aid in predicting the primary site. In selected cases, electron microscopy (EM) and chromosomal analysis should be considered if other results are inconclusive. Repeat biopsy is indicated if tissue from the initial biopsy is insufficient for these additional diagnostic tests. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Molecular cancer classifier assays'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Immunohistochemistry</span><span class="headingEndMark"> — </span>IHC is particularly valuable in identifying the tumor lineage (carcinoma versus lymphoma versus sarcoma, etc) in patients with poorly differentiated neoplasm  (<a class="graphic graphic_table graphicRef62750" href="/z/d/graphic/62750.html" rel="external">table 1</a>). Once a poorly differentiated carcinoma has been identified, IHC can sometimes suggest a specific tumor type and/or primary site  (<a class="graphic graphic_table graphicRef56518" href="/z/d/graphic/56518.html" rel="external">table 2</a>). IHC uses antibodies that are directed at specific cell components or products including enzymes, normal tissue components, hormones, and tumor markers. Such staining can be performed on formalin-fixed, paraffin-embedded tissue. Considerable technical expertise is required to perform these tests, and proper interpretation requires an experienced pathologist.</p><p>No IHC staining pattern is completely specific. However, a specific diagnosis is often suggested by the IHC results. A few stains (eg, leukocyte common antigen [LCA] for lymphoma; prostate specific antigen [PSA] for prostate cancer) are quite specific and rarely yield false-positive results. Most IHC stains are less specific and must be interpreted in conjunction with light microscopic and clinical features. The use of panels of IHC stains can also improve the diagnostic specificity, particularly in the differential diagnosis of various adenocarcinomas. To further complicate interpretation, some poorly differentiated neoplasms lose all specific IHC markers, prohibiting further characterization by IHC.</p><p>Examples of the potential utility of IHC in the evaluation of poorly differentiated neoplasms include:</p><p class="bulletIndent1"><span class="glyph">●</span>Monoclonal antibodies that react with antigens present on human white blood cells can reliably differentiate hematologic from nonhematologic neoplasms in formalin-fixed sections [<a href="#rid4">4-8</a>]. In one study, immunostaining for LCA (CD45) was applied to 315 lymphomas and 420 nonhematologic tumors [<a href="#rid9">9</a>]. All of the non-Hodgkin lymphomas, 12 of 25 Hodgkin lymphomas, and none of the non-hematologic tumors were LCA positive.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive staining for cytokeratins (EMA, AE1/AE3) provides strong evidence for a carcinoma [<a href="#rid10">10-12</a>], although rarely positive in anaplastic undifferentiated lymphoma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive staining for vimentin or desmin, in the absence of staining for cytokeratins, is suggestive of sarcoma [<a href="#rid10">10-12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive staining for S100 protein, HMB-45 antigen, and vimentin supports the diagnosis of amelanotic melanoma [<a href="#rid13">13,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive staining for factor VIII-related antigen is a specific but not sensitive marker for angiosarcoma [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive staining for c-kit (CD117) supports the diagnosis of a gastrointestinal stromal tumor [<a href="#rid17">17</a>].</p><p></p><p>After a poorly differentiated cancer is recognized to be a carcinoma, IHC staining can sometimes provide further characterization  (<a class="graphic graphic_table graphicRef56518" href="/z/d/graphic/56518.html" rel="external">table 2</a>). Panels of IHC stains are more effective than single stains [<a href="#rid18">18-20</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>A neuroendocrine carcinoma (eg, small cell/large cell lung cancer, carcinoid, islet cell tumor) is suggested by positive immunostaining for chromogranin A or synaptophysin [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunostaining for PSA is quite specific for prostate cancer [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>IHC staining for octamer binding transcription factor 4 (OCT4, also called POU domain class 5 transcription factor 1) establishes a germ cell origin for a tumor [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specific combinations of IHC staining  (<a class="graphic graphic_table graphicRef56518" href="/z/d/graphic/56518.html" rel="external">table 2</a>) provide strong evidence for the diagnosis of adenocarcinomas arising in the colon, lung, kidney, or thyroid.</p><p></p><p class="headingAnchor" id="H1568146501"><span class="h2">Molecular cancer classifier assays</span><span class="headingEndMark"> — </span>Molecular cancer classifier assays (MCCAs) are diagnostic gene expression profiling assays that can predict the tissue of tumor origin in patients with CUP. This technique is based on the detection of a site-specific gene expression profile, with some assays demonstrating an accuracy rate of approximately 80 percent [<a href="#rid24">24-27</a>]. MCCAs provide information that is distinct from comprehensive molecular profiling or sequencing, which detects molecular alterations in the cancer and usually cannot identify the site of tumor origin. The role of MCCAs in the diagnosis and management of patients with CUP is evolving, but most evidence suggests the benefit of site-specific therapy, based on the MCCA predictions, in patients with treatment-sensitive tumor types. MCCAs have best been evaluated in adenocarcinoma of unknown primary, and further discussion is detailed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Molecular cancer classifier assays'</a>.)</p><p>Although data are limited, MCCAs appear to be valuable in the diagnosis of patients with poorly differentiated neoplasms of unknown primary site. As an example, in a group of 30 patients who retained this diagnosis after extensive IHC evaluation (median 18 IHC stains), MCCAs predicted the tumor lineage in 83 percent (carcinoma 10, sarcoma 8, melanoma 5, lymphoma 2) [<a href="#rid28">28</a>]. Additional directed testing supported the MCCA diagnoses in 11 of 15 patients. Specific sites of origin were predicted for all 10 carcinomas (including three germ cell tumors and two neuroendocrine carcinomas). Although the study was retrospective, the diagnosis determined by MCCA was used to direct therapy in seven patients (two germ cell, two neuroendocrine, two mesothelioma, one lymphoma), and five remained progression free for 25 to 72+ months.</p><p>Gene sequencing techniques (such as comprehensive molecular profiling and assaying specific targetable molecular alterations) may be useful in finding actionable genetic alterations in the tumors of some CUP patients and is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Comprehensive molecular profiling'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Electron microscopy</span><span class="headingEndMark"> — </span>Electron microscopy requires special tissue cutting and fixation, and is relatively expensive. For these reasons, electron microscopy should be reserved for neoplasms whose lineage remains unclear after light microscopy, IHC staining, and MCCA.</p><p>Electron microscopy is extremely reliable in distinguishing lymphoma from carcinoma and is probably superior to IHC for the identification of poorly differentiated sarcomas. The presence of structures such as neurosecretory granules in neuroendocrine tumors and premelanosomes in melanoma can help identify these neoplasms.</p><p>Electron microscopy can also provide evidence for adenocarcinoma or squamous cell carcinoma in cases in which light microscopy is not distinctive. However, it is usually impossible to pinpoint the origin of poorly differentiated adenocarcinomas or squamous cell carcinomas by electron microscopic studies since few ultrastructural features are specific for any site of origin [<a href="#rid29">29</a>].</p><p>Undifferentiated tumors often lose specific ultrastructural features as well as typical histology. For this reason, the absence of a particular ultrastructural finding cannot be used to rule out a specific diagnosis.</p><p class="headingAnchor" id="H5"><span class="h2">Chromosome analysis</span><span class="headingEndMark"> — </span>The identification of tumor-specific chromosome abnormalities has allowed the application of cytogenetic analysis to the evaluation of poorly differentiated neoplasms of unknown primary site in selected cases.</p><p>The utility of cytogenetic analysis can be illustrated by the following:</p><p class="bulletIndent1"><span class="glyph">●</span>The majority of B cell lymphomas contain immunoglobulin (Ig) gene rearrangements, and they usually express a unique clonal surface Ig that provides a specific tumor marker [<a href="#rid30">30-32</a>]. In lymphomas that lack detectable surface or cytoplasmic Ig, diagnostic clonal gene rearrangements are often demonstrable. (See  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a> and  <a class="medical medical_review" href="/z/d/html/2893.html" rel="external">"Tools for genetics and genomics: Cytogenetics and molecular genetics"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A specific chromosomal translocation (t[11;22] [q24;q12]) is found in all peripheral primitive neuroectodermal tumors and is also frequent in Ewing sarcoma [<a href="#rid33">33,34</a>]. (See  <a class="medical medical_review" href="/z/d/html/7737.html" rel="external">"Pathogenetic factors in soft tissue and bone sarcomas"</a> and  <a class="medical medical_review" href="/z/d/html/7742.html" rel="external">"Epidemiology, pathology, and molecular genetics of Ewing sarcoma", section on 'Molecular genetics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An isochromosome of the short arm of chromosome 12 (i12p) can be detected in a large percentage of testicular and extragonadal germ cell tumors in males [<a href="#rid35">35,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A chromosomal translocation of the NUT gene is associated with aggressive, refractory midline carcinoma in children and young adults [<a href="#rid37">37</a>]. (See <a class="local">'NUT midline carcinoma'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Detection of the Epstein-Barr virus genome can be an indicator of nasopharyngeal carcinoma in patients with metastatic disease in cervical lymph nodes and an undetermined primary site. (See  <a class="medical medical_review" href="/z/d/html/3404.html" rel="external">"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma", section on 'Epstein-Barr virus'</a> and  <a class="medical medical_review" href="/z/d/html/3404.html" rel="external">"Epidemiology, etiology, and diagnosis of nasopharyngeal carcinoma", section on 'Introduction'</a>.)</p><p></p><p class="headingAnchor" id="H7"><span class="h1">TREATMENT AND PROGNOSIS</span><span class="headingEndMark"> — </span>In patients with poorly differentiated neoplasms of unknown primary site, the ability to distinguish between different tumor types can have very important prognostic and/or therapeutic implications.</p><p>When specialized diagnostic studies identify a treatable neoplasm, therapy should follow guidelines established for that tumor. Examples of treatable tumor types occasionally identified in these patients include neuroendocrine carcinoma, Ewing sarcoma family of neoplasms, and a variety of primitive sarcomas. Other important tumor groups that may be identified are discussed in this section.</p><p class="headingAnchor" id="H8"><span class="h2">Lymphomas</span><span class="headingEndMark"> — </span>Undifferentiated neoplasms that are identified as lymphoma respond well to the same combination chemotherapy regimens that are used for aggressive non-Hodgkin lymphoma. (See  <a class="medical medical_review" href="/z/d/html/4729.html" rel="external">"Initial treatment of advanced stage diffuse large B cell lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4749.html" rel="external">"Initial treatment of peripheral T cell lymphoma"</a>.)</p><p>In a group of 35 patients with histologically unclassified neoplasms that were identified as lymphoma by LCA staining, treatment with standard lymphoma treatment regimens (CHOP and variants) produced an actuarial disease-free survival of 45 percent at 30 months [<a href="#rid38">38</a>]. This outcome was similar to that for a group of concurrently treated patients with aggressive lymphoma and typical histology.</p><p class="headingAnchor" id="H1568145737"><span class="h2">Extragonadal germ cell tumors</span><span class="headingEndMark"> — </span>A few patients with poorly differentiated neoplasm or poorly differentiated carcinoma of unknown primary site have extragonadal germ cell tumors that are unrecognizable by standard histologic criteria. These patients typically have some of the following characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>Young age</p><p class="bulletIndent1"><span class="glyph">●</span>Male sex</p><p class="bulletIndent1"><span class="glyph">●</span>Predominant tumor location in the mediastinum or retroperitoneum</p><p class="bulletIndent1"><span class="glyph">●</span>Marked elevation of the serum human chorionic gonadotropin (hCG) or alpha-fetoprotein (AFP) levels</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of 12p chromosomal gain (isochromosome 12p)</p><p class="bulletIndent1"><span class="glyph">●</span>Immunohistochemical staining for OCT4 or placental leukocyte alkaline phosphatase (PLAP) [<a href="#rid23">23</a>]</p><p></p><p>Most young men with poorly differentiated neoplasm or carcinoma and features of extragonadal germ cell tumor have an excellent response to chemotherapy, and some are cured with cisplatin-based regimens. For this reason, all patients with poorly differentiated neoplasm/carcinoma or poorly differentiated adenocarcinoma of unknown primary site who have these characteristics should be treated according to the guidelines established for poor prognosis germ cell tumors. (See  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors"</a>.)</p><p class="headingAnchor" id="H1568145977"><span class="h2">Poorly differentiated carcinoma without characteristics of germ cell tumor</span><span class="headingEndMark"> — </span>Most patients with poorly differentiated carcinoma of unknown primary site do not have features typical of extragonadal germ cell tumor, and an empiric trial of chemotherapy has been recommended. Several investigators have reported higher overall response rates in this group when compared with patients with adenocarcinoma of unknown primary site, particularly when platinum-based regimens are used [<a href="#rid39">39-42</a>]. In addition, some investigators have reported a minority (15 percent) of patients with complete response and long-term survival [<a href="#rid43">43</a>], while others have not observed such a subset.</p><p>While these older results were important in demonstrating the heterogeneity of this patient population, it is likely that currently available diagnostic methods are effective in identifying the highly responsive patients within this large group. Some of these patients have clinical or pathologic features that fit into one of the treatable subgroups described for adenocarcinoma and should be treated accordingly. In other patients, a specific tumor lineage or site of origin can be established. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Specific patient subgroups'</a>.)</p><p>Although data remain incomplete, support for site-specific therapy directed by the results of IHC stains or MCCA, rather than empiric chemotherapy, is becoming increasingly compelling, with most data in patients with adenocarcinoma of unknown primary site. However, it seems likely that MCCA will also be effective in directing treatment for patients with poorly differentiated carcinoma. For these reasons, the treatment approach for patients with poorly differentiated carcinoma should follow the guidelines used for patients with adenocarcinoma of unknown primary site. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Approach to patients not included in specific subgroups'</a>.)</p><p>Data are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Validation of the available MCCAs was performed in patients with known primary tumors, including both adenocarcinoma and poorly differentiated carcinoma histology. Accuracy was similar regardless of histology.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one prospective study, 18 percent of patients had poorly differentiated carcinoma, and an additional 24 percent had poorly differentiated adenocarcinoma [<a href="#rid44">44</a>]. In this study, site-specific treatment directed by MCCA results led to a median survival of 12.5 months in the entire group of 194 patients. Those predicted to have more responsive tumor types had longer median survival than did those with less responsive types (13.4 versus 7.6 months, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In two studies, patients predicted by MCCA to have responsive cancer types had longer survival than did those with unresponsive cancer types [<a href="#rid45">45,46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective series of CUP patients who had the diagnosis of poorly differentiated neoplasm after extensive immunohistochemistry (IHC) evaluation, MCCA predicted the tumor lineage and/or site of origin in 25 of 30 patients (83 percent) [<a href="#rid28">28</a>].</p><p></p><p>The choice between empiric chemotherapy and site-specific therapy based on IHC or MCCA prediction remains controversial in patients with CUP. Several studies comparing site-specific treatment and empiric chemotherapy in patients with CUP have been reported [<a href="#rid47">47-49</a>]. In randomized studies, the results of the two treatment approaches were similar [<a href="#rid47">47,48</a>]; however, the majority of patients had treatment-resistant tumor types, in which the impact of site-specific treatment is minimal. Numbers of patients with treatment-sensitive tumor types (who would be expected to derive most benefit from site-specific treatment) were too small to be meaningfully compared. These data are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Cancers with predicted treatment sensitivity'</a>.)</p><p>The authors strongly prefer site-specific treatment for patients with treatment-sensitive tumor types. Either empiric chemotherapy or site-specific treatment is acceptable in treatment-resistant tumor types. If empiric chemotherapy is selected in these patients, a platinum-based regimen is probably preferable [<a href="#rid40">40-42,50-53</a>]. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Approach to patients not included in specific subgroups'</a>.)</p><p class="headingAnchor" id="H1568146612"><span class="h2">NUT midline carcinoma</span><span class="headingEndMark"> — </span>NUT midline carcinomas are defined by the presence of a chromosomal rearrangement of the <em>NUT</em> gene [<a href="#rid37">37,54</a>]. The molecular translocation involves the <em>BRD4</em> or <em>BRD3</em> gene in most cases, but translocation of other genes has also been described. NUT midline carcinomas are aggressive, poorly differentiated tumors that include variable degrees of squamous differentiation in approximately one-half of cases.</p><p>In a retrospective analysis that included 141 cases of NUT midline carcinoma from the NUT Midline Carcinoma Registry compiled over a 24-year period, the median age at diagnosis was 23.6 years; 51 percent of patients had predominant tumor location in the thorax, and 49 percent had other sites (head/neck, soft tissue, bone, others) [<a href="#rid37">37</a>]. More than 60 percent of patients had one or more sites of metastases. The median overall survival was 6.5 months for all patients regardless of therapy, but three risk groups were defined by anatomic site and NUT fusion type: thoracic tumor (n = 67), median survival 4.4 months; nonthoracic tumor with <em>BDR4-NUT</em> alteration (n = 45), median survival 10 months; and nonthoracic tumor with <em>BRD3</em>- or <em>NSD3-NUT</em> alteration (n = 12), median survival 36.5 months.</p><p>More cases of NUT midline carcinoma are being diagnosed, presumably due to increased awareness of this entity and better diagnostic capabilities. The commercially available C52 monoclonal antibody can be used for IHC testing of poorly differentiated carcinomas without glandular differentiation that arise in the chest or head and neck [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic evaluation</strong> – Light microscopy generally cannot establish a diagnosis in patients with poorly differentiated cancers of unknown primary site (CUPs). Specialized studies, including immunohistochemistry, molecular cancer classifier assays, and in selected cases, electron microscopy and/or chromosomal analysis, can usually distinguish between a diagnosis of carcinoma, germ cell tumor, lymphoma, melanoma, or sarcoma. (See <a class="local">'Pathologic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment and prognosis</strong> – When specialized pathologic studies are consistent with a diagnosis of poorly differentiated lymphoma, extragonadal germ cell tumor, melanoma, or sarcoma, treatment should be based upon that diagnostic category. (See <a class="local">'Treatment and prognosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of patients in treatable subgroups</strong> – Several clinical subsets requiring specific treatment have been defined for patients with adenocarcinoma of unknown primary site. Patients with poorly differentiated carcinoma who fit into one of these clinical subsets should receive treatment as described for adenocarcinoma. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Specific patient subgroups'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of patients not included in specific subgroups</strong> – For other patients with poorly differentiated carcinoma who do not fit into any treatable subgroup, the information derived from immunohistochemistry and molecular cancer classifier assay often suggests the site of origin. Optimal therapy for these patients is controversial, and the treatment approach is similar to patients with adenocarcinoma of unknown primary. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Approach to patients not included in specific subgroups'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients predicted to have treatment-sensitive tumor types, we favor site-specific therapy. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Cancers with predicted treatment sensitivity'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with treatment-resistant tumor types, empiric chemotherapy with a platinum-based regimen or site-specific treatment produces similar results; either approach is acceptable. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Cancers with predicted treatment resistance or no primary site identified'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Comprehensive molecular profiling of biopsy specimens or liquid biopsies may identify important therapeutic targets for some patients. (See  <a class="medical medical_review" href="/z/d/html/4877.html" rel="external">"Adenocarcinoma of unknown primary site", section on 'Comprehensive molecular profiling'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Rassy E, Pavlidis N. The currently declining incidence of cancer of unknown primary. Cancer Epidemiol 2019; 61:139.</a></li><li><a class="nounderline abstract_t">Møller AK, Loft A, Berthelsen AK, et al. A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site. Oncologist 2012; 17:1146.</a></li><li><a class="nounderline abstract_t">Hainsworth JD, Wright EP, Gray GF Jr, Greco FA. Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy. J Clin Oncol 1987; 5:1275.</a></li><li><a class="nounderline abstract_t">Battifora H, Trowbridge IS. A monoclonal antibody useful for the differential diagnosis between malignant lymphoma and nonhematopoietic neoplasms. Cancer 1983; 51:816.</a></li><li><a class="nounderline abstract_t">Gabbiani G, Kapanci Y, Barazzone P, Franke WW. Immunochemical identification of intermediate-sized filaments in human neoplastic cells. A diagnostic aid for the surgical pathologist. Am J Pathol 1981; 104:206.</a></li><li><a class="nounderline abstract_t">Nagle RB, McDaniel KM, Clark VA, Payne CM. The use of antikeratin antibodies in the diagnosis of human neoplasms. Am J Clin Pathol 1983; 79:458.</a></li><li><a class="nounderline abstract_t">Schlegel R, Banks-Schlegel S, McLeod JA, Pinkus GS. Immunoperoxidase localization of keratin in human neoplasms: a preliminary survey. Am J Pathol 1980; 101:41.</a></li><li><a class="nounderline abstract_t">Warnke RA, Gatter KC, Falini B, et al. Diagnosis of human lymphoma with monoclonal antileukocyte antibodies. N Engl J Med 1983; 309:1275.</a></li><li><a class="nounderline abstract_t">Michels S, Swanson PE, Frizzera G, Wick MR. Immunostaining for leukocyte common antigen using an amplified avidin-biotin-peroxidase complex method and paraffin sections. A study of 735 hematopoietic and nonhematopoietic human neoplasms. Arch Pathol Lab Med 1987; 111:1035.</a></li><li><a class="nounderline abstract_t">Denk H, Krepler R, Artlieb U, et al. Proteins of intermediate filaments. An immunohistochemical and biochemical approach to the classification of soft tissue tumors. Am J Pathol 1983; 110:193.</a></li><li><a class="nounderline abstract_t">Osborn M, Weber K. Tumor diagnosis by intermediate filament typing: a novel tool for surgical pathology. Lab Invest 1983; 48:372.</a></li><li><a class="nounderline abstract_t">Ramaekers FC, Vroom TM, Moesker O, et al. The use of antibodies to intermediate filament proteins in the differential diagnosis of lymphoma versus metastatic carcinoma. Histochem J 1985; 17:57.</a></li><li><a class="nounderline abstract_t">Kahn HJ, Marks A, Thom H, Baumal R. Role of antibody to S100 protein in diagnostic pathology. Am J Clin Pathol 1983; 79:341.</a></li><li><a class="nounderline abstract_t">Mottolese M, Venturo I, Benevolo M, et al. Immunocytochemical diagnosis of amelanotic metastatic melanoma using monoclonal antibodies HMB-45 and Ep1-3. Melanoma Res 1994; 4:53.</a></li><li><a class="nounderline abstract_t">Ohsawa M, Naka N, Tomita Y, et al. Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases. Cancer 1995; 75:2867.</a></li><li><a class="nounderline abstract_t">Leader M, Collins M, Patel J, Henry K. Staining for factor VIII related antigen and Ulex europaeus agglutinin I (UEA-I) in 230 tumours. An assessment of their specificity for angiosarcoma and Kaposi's sarcoma. Histopathology 1986; 10:1153.</a></li><li><a class="nounderline abstract_t">Miettinen M, Lasota J. Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1.</a></li><li><a class="nounderline abstract_t">Park SY, Kim BH, Kim JH, et al. Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 2007; 131:1561.</a></li><li><a class="nounderline abstract_t">Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol 2010; 18:3.</a></li><li><a class="nounderline abstract_t">Oien KA, Dennis JL. Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling. Ann Oncol 2012; 23 Suppl 10:x271.</a></li><li><a class="nounderline abstract_t">O'Connor DT, Burton D, Deftos LJ. Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues. J Clin Endocrinol Metab 1983; 57:1084.</a></li><li><a class="nounderline abstract_t">Allhoff EP, Proppe KH, Chapman CM, et al. Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer. J Urol 1983; 129:315.</a></li><li><a class="nounderline abstract_t">Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer 2004; 101:2006.</a></li><li><a class="nounderline abstract_t">Greco FA, Spigel DR, Yardley DA, et al. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist 2010; 15:500.</a></li><li><a class="nounderline abstract_t">Greco FA, Lennington WJ, Spigel DR, Hainsworth JD. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology. J Natl Cancer Inst 2013; 105:782.</a></li><li><a class="nounderline abstract_t">Kerr SE, Schnabel CA, Sullivan PS, et al. Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res 2012; 18:3952.</a></li><li><a class="nounderline abstract_t">Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001; 61:7388.</a></li><li><a class="nounderline abstract_t">Greco FA, Lennington WJ, Spigel DR, Hainsworth JD. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay. Mol Diagn Ther 2015; 19:91.</a></li><li><a class="nounderline abstract_t">Hammar SP. Metastatic adenocarcinoma of unknown primary origin. Hum Pathol 1998; 29:1393.</a></li><li><a class="nounderline abstract_t">Arnold A, Cossman J, Bakhshi A, et al. Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms. N Engl J Med 1983; 309:1593.</a></li><li><a class="nounderline abstract_t">Cleary ML, Chao J, Warnke R, Sklar J. Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc Natl Acad Sci U S A 1984; 81:593.</a></li><li><a class="nounderline abstract_t">Lossos IS, Okada CY, Tibshirani R, et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood 2000; 95:1797.</a></li><li><a class="nounderline abstract_t">Turc-Carel C, Aurias A, Mugneret F, et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988; 32:229.</a></li><li><a class="nounderline abstract_t">Whang-Peng J, Triche TJ, Knutsen T, et al. Chromosome translocation in peripheral neuroepithelioma. N Engl J Med 1984; 311:584.</a></li><li><a class="nounderline abstract_t">Bosl GJ, Ilson DH, Rodriguez E, et al. Clinical relevance of the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 1994; 86:349.</a></li><li><a class="nounderline abstract_t">Wehle D, Yonescu R, Long PP, et al. Fluorescence in situ hybridization of 12p in germ cell tumors using a bacterial artificial chromosome clone 12p probe on paraffin-embedded tissue: clinical test validation. Cancer Genet Cytogenet 2008; 183:99.</a></li><li><a class="nounderline abstract_t">Chau NG, Ma C, Danga K, et al. An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectr 2020; 4:pkz094.</a></li><li><a class="nounderline abstract_t">Horning SJ, Carrier EK, Rouse RV, et al. Lymphomas presenting as histologically unclassified neoplasms: characteristics and response to treatment. J Clin Oncol 1989; 7:1281.</a></li><li><a class="nounderline abstract_t">Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer 2004; 100:1257.</a></li><li><a class="nounderline abstract_t">Greco FA, Burris HA 3rd, Erland JB, et al. Carcinoma of unknown primary site. Cancer 2000; 89:2655.</a></li><li><a class="nounderline abstract_t">Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 2000; 11:211.</a></li><li><a class="nounderline abstract_t">Briasoulis E, Kalofonos H, Bafaloukos D, et al. Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 2000; 18:3101.</a></li><li><a class="nounderline abstract_t">Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience. J Clin Oncol 1992; 10:912.</a></li><li><a class="nounderline abstract_t">Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute. J Clin Oncol 2013; 31:217.</a></li><li><a class="nounderline abstract_t">Moran S, Martínez-Cardús A, Sayols S, et al. Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. Lancet Oncol 2016; 17:1386.</a></li><li><a class="nounderline abstract_t">Yoon HH, Foster NR, Meyers JP, et al. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance). Ann Oncol 2016; 27:339.</a></li><li><a class="nounderline abstract_t">Hayashi H, Kurata T, Takiguchi Y, et al. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. J Clin Oncol 2019; 37:570.</a></li><li><a class="nounderline abstract_t">Fizasi K, Maillard A, Penel N, et al. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Ann Oncol 2019; 30:5S.</a></li><li><a class="nounderline abstract_t">Hayashi H, Takiguchi Y, Minami H, et al. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial. JAMA Oncol 2020; 6:1931.</a></li><li><a class="nounderline abstract_t">Culine S, Lortholary A, Voigt JJ, et al. Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 2003; 21:3479.</a></li><li><a class="nounderline abstract_t">Hainsworth JD, Erland JB, Kalman LA, et al. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide. J Clin Oncol 1997; 15:2385.</a></li><li><a class="nounderline abstract_t">Greco FA, Burris HA 3rd, Litchy S, et al. Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 2002; 20:1651.</a></li><li><a class="nounderline abstract_t">Greco FA, Rodriguez GI, Shaffer DW, et al. Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial. Oncologist 2004; 9:644.</a></li><li><a class="nounderline abstract_t">French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012; 7:247.</a></li></ol></div><div id="topicVersionRevision">Topic 4875 Version 23.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31254795" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The currently declining incidence of cancer of unknown primary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22711751" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2442318" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6336985" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A monoclonal antibody useful for the differential diagnosis between malignant lymphoma and nonhematopoietic neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6170230" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Immunochemical identification of intermediate-sized filaments in human neoplastic cells. A diagnostic aid for the surgical pathologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6188361" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The use of antikeratin antibodies in the diagnosis of human neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6160769" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Immunoperoxidase localization of keratin in human neoplasms: a preliminary survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6355845" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Diagnosis of human lymphoma with monoclonal antileukocyte antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2444189" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Immunostaining for leukocyte common antigen using an amplified avidin-biotin-peroxidase complex method and paraffin sections. A study of 735 hematopoietic and nonhematopoietic human neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6824065" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Proteins of intermediate filaments. An immunohistochemical and biochemical approach to the classification of soft tissue tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6187996" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Tumor diagnosis by intermediate filament typing: a novel tool for surgical pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2580816" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The use of antibodies to intermediate filament proteins in the differential diagnosis of lymphoma versus metastatic carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6299096" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Role of antibody to S100 protein in diagnostic pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8032219" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Immunocytochemical diagnosis of amelanotic metastatic melanoma using monoclonal antibodies HMB-45 and Ep1-3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7773935" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3100411" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Staining for factor VIII related antigen and Ulex europaeus agglutinin I (UEA-I) in 230 tumours. An assessment of their specificity for angiosarcoma and Kaposi's sarcoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213830" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Gastrointestinal stromal tumors--definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17922593" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19550296" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22987975" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6352725" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6339742" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Evaluation of prostate specific acid phosphatase and prostate specific antigen in identification of prostatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15386301" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20427384" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23641043" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22648269" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11606367" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Molecular classification of human carcinomas by use of gene expression signatures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25758902" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9865824" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Metastatic adenocarcinoma of unknown primary origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6417538" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Immunoglobulin-gene rearrangements as unique clonal markers in human lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6607475" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10688840" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3163261" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6749231" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Chromosome translocation in peripheral neuroepithelioma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8308927" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical relevance of the i(12p) marker chromosome in germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18503827" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Fluorescence in situ hybridization of 12p in germ cell tumors using a bacterial artificial chromosome clone 12p probe on paraffin-embedded tissue: clinical test validation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32328562" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2671285" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Lymphomas presenting as histologically unclassified neoplasms: characteristics and response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15022294" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11135228" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Carcinoma of unknown primary site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10761758" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Carcinoma of unknown primary site: phase II trials with docetaxel plus cisplatin or carboplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10963638" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1375284" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23032625" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27575023" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26578722" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30653423" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33057591" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12972523" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9196154" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11896116" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15561808" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22017582" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pathogenesis of NUT midline carcinoma.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
